“Dave AI”: a Game-Changer app for cancer patients

May 2024.

Oncologists often share that people knowledgeable about their cancer type and treatment possibilities have the potential to become savvy survivors. Pancreatic cancer communities such as Let’s Win for Pancreatic Cancer, which crowd-sources clinical trial possibilities, have demonstrated that a more engaged patient has better access to clinical trials and treatment innovation. Why shouldn’t all people diagnosed with cancer have a 24/7 mentor and coach to navigate the uphill care path?  That’s precisely what Belong-Life has created – an ever-smart mentor and care partner called Dave AI.

The LLM Cancer Mentor App is a revolutionary tool for cancer patients, caregivers, and physicians. It’s like having a WAZE for navigating the complex cancer diagnostic and care journey.  No longer do patients have to wait for their next appointment to get answers to their questions. They now have a high-level concierge coach available 24/7, ushering in what innovation theorist John Nosta calls ‘The Age of Cognition ‘.

“Perhaps one of the most complex things about oncology is complexity itself. From clinical knowledge and understanding to articulating difficult concepts with patients. Part of what large language models (LLMs) offer is the ability to provide a cognitive assistant that serves up information that is organized and important, and delivers it away that is more relevant and understandable,” said Nosta to Medika Life. “This is perhaps most important with patients who often find the complexity of oncology to be one of the worst toxicities of both therapy and disease,” he added.

ChatGPT Controversial Perhaps, But Patient Preferred

Last year, a controversial JAMA study suggested patients often preferred ChatGPT tools to physician conversation.  A chatbot generated quality and empathetic responses to patient questions online in this cross-sectional study.  While physicians doubted the study’s design, it was evident from data and public conversation that technology available in real-time answering patients’ pressing clinical and emotional needs was sought and welcomed. Even Eric Topol, MD, a long-time AI advocate reports that augmented information can potentially save lives.

Now, the large language model (LLM) called Dave AI was created by Belong.Life increases patient engagement and provides personalized support.  Medika Life spoke with one of the world’s foremost digital health leaders, who marshaled the potential of technology and tapped medical and drug development experts and patient feedback systems to develop AI, ChatGPT, and LLMs tools to support cancer patient advocacy and innovation.  Eliran Malki, the co-founder and CEO of Belong.Life, is a proven entrepreneur and business leader who has founded, financed, and led several successful companies, including More IT Resources Ltd., acquired by Dell-EMC, Veracity Ltd., acquired by EMET, and others.  Together with Co-Founder Irad Deutsch, they launched Belong.Life almost a decade ago. Today, the company serves patients around the globe.

Malki’s blueprint for success isn’t a closely guarded secret – he consistently creates tech platforms that provide easily accessible, practical, and consistent value to users.  Belong.Life is a multilingual HIPAA, GDPR, and ISO-compliant community combining science, service, and solutions to unite patients, payors, product innovators, policymakers, and provers. It demonstrates that the LLMs can provide patients with the support essential to their cancer care journey – augmented information on-demand.

The  Dave Cancer Mentor app can be downloaded here.

Read the Full Article >

More Articles

Dave AI – a Revolutionary Tool for Cancer Patients

Promise and Peril of Instant Health Information Access for Consumers. Apps and AI Help Patients…

Dave AI: The Shining Star of TIME’s List 2024

From a pregnancy monitor to a beehive monitor, see which Israeli inventions were chosen for…
Market Leader

Belong Staring at the Top of Oncology Solutions with AI-Driven Cancer Care

Read the full article >…
Skip to content